Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of brostallicin versus doxorubicin in advanced or metastatic soft tissue sarcoma
2006-001861-40Phase 2Completed
- Sponsor
- Systems Medicine
- Start
- Jul 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of brostallicin in soft tissue sarcoma (STS) (2 arms), sponsored by Systems Medicine. Primary endpoint: 6-month progression-free survival. Started Jul 2006; status: completed.
02
Drugs
brostallicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2006-001861-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001861-40.